GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
SAN DIEGO, May 08, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, publishes scientific posters with dynamic audio narration. More than a dozen posters were presented at the recent American Association of Cancer Research’s (AACR) 2018 meeting and are now available to watch and download, https://www.crownbio.com/posters/
These scientific posters describe innovations in CrownBio’s Internal R&D focusing on preclinical oncology research. The most compelling work is now available on-demand and narrated by CrownBio scientists. The library of poster presentations includes details on the development and application of several innovative humanized models, a new largescale ex vivo PDX drug screening service and a novel IDO1 inhibition assay platform. Collectively, the data demonstrate CrownBio’s unique capacity to enhance knowledge, guide development decisions and advance immunotherapy programs.
“CrownBio is providing unfettered access to CrownBio’s innovative research with scientific colleagues worldwide,” said Dr. Henry Li, CrownBio’s Vice President of Translational Oncology. “We are committed to sharing with scientists globally the cutting-edge tools that are available to accelerate, inform and enlighten contemporary evaluation of cancer therapies and immunotherapies.”
“Crown Bioscience is committed to making valuable contributions to the scientific community,” said Dr. Jean Pierre Wery, Crown Bioscience’s Chief Executive Officer. “By providing these posters, narrated by the experts behind the science, we hope to deliver insights researchers can use to advance their preclinical drug development programs.”
The library of narrated posters can be found on Crown Bioscience’s website, https://www.crownbio.com/posters/
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. [email protected]
